Measurement and clinical study on serum monocyte chemoattractant protein-1 in patients with acute cerebral infarction

Abstract

Objective To measure the level of serum monocyte chemoattractant protein-1 (MCP-1) in patients with acute cerebral infarction and explore its significance on treatment of cerebrovascular diseases. Methods One hundred and one patients with acute cerebral infarction were divided into group A (NIHSS>5) and group B (NIHSS≤5). Forty healthy subjects were chosen as control group. The serum MCP-1 levels in these 3 groups were measured and the correlation between the level of MCP-1 and the scores of NIHSS were analyzed. The death and any new vascular events were recorded during the follow-up for 6 months and then the correlation between the level of MCP-1 and prognosis of acute cerebral infarction was analyzed. Results The level of MCP-1 in patients with acute cerebral infarction was significantly higher than that in the control group. Group A showed a significantly higher level of MCP-1 than group B. The patients with a MCP-1 level of lower than or equal to 133.90 pg/mL enjoyed good prognoses as compared with those with a level of higher than 133.90 pg/mL. The NIHSS scores and the prognosis of acute cerebral infarction were positively correlated (r =0.244.P=0.014). Conclusion Compared with that in the control group, the MCP-1 level in patients with acute cerebral infarction is significantly higher and has a positive correlation with the severity of infarction. MCP-1 level is somewhat valuable in the prognosis of patients with acute cerebral infarction that have an onset less than halfa year. Key words: Acute cerebral infarction; Monocyte chemoattractant protein-1; Biomarkers; Inflammation; Prognosis